SZSE Biological Medicine 50 Index (399280) News

Multiple major broad-based index rebalancings will take place this Friday, adding leading solar and semiconductor stocks, affecting ETF assets totaling nearly RMB 700 billion.

① The adjustments to major broad-based indices, including the CSI 300 and CSI A500, will take effect after the market closes this Friday, with the total assets under management of all ETFs tracking these indices amounting to RMB 693.452 billion; ② Multiple indices have seen an increase in their 'technology content,' as key companies in sectors such as memory storage, optical communications, wafer foundry, and photonic chips have been added to several broad-based indices.

cls.cnJun 9 17:50

Breaking News! This company’s annual report contains false statements and will be subject to other risk warnings | After-Hours Announcement Summary

Sinuo邦 Signs Electrolyte Supply Agreement with CATL, with Estimated Total Purchases of 300,000 Tonnes from 2026 to 2028

cls.cnJun 7 18:13

Boteng Co., Ltd. to Discontinue Investment in European Facility Amid Expected Impairment Provisions Exceeding RMB 330 Million | Quick Read Announcement

① In light of Novartis having issued a notice of termination to PSI, Boteng Co., Ltd. has officially announced the termination of its planned investment in the R&D and manufacturing facility in Slovenia. ② As a result of this project termination, the company’s finance department has preliminarily estimated that an impairment loss of approximately RMB 330 million to RMB 400 million will be recognized in 2026.

cls.cnJun 6 13:05

Sinopharm Group to Acquire 20% Stake in Adicon for RMB 1.6 Billion, with Five-Year Share Lock-Up and Control Over Board Renewal | Quick Read Announcement

① China National Pharmaceutical Group (Sinopharm) plans to acquire a 20% stake in AmoyDx for RMB 1.654 billion, with a five-year lock-up period on the shares; ② Following the transaction, Sinopharm will lead the board renewal process and nominate the chairman and key senior executives; ③ In recent years, Sinopharm has successively acquired stakes in companies such as Pulanbio and Shandong Pharmaceutical Glass, and the number of its listed subsidiaries could expand to 11.

cls.cnJun 4 23:58

Optical communications stocks surge overseas with major win: secure $460 million order from U.S. client | Selected after-hours announcements

An emerging company in the optical communications sector has secured RMB 460 million in orders from U.S. clients; a leader in precision medicine within the pharmaceutical industry is set to be acquired by a major state-owned enterprise; and a leading financial IT firm has crossed into a new venture, establishing a joint venture to tap into the 'computing power leasing' market... What notable announcements emerged after today's market close?

Golden10 DataJun 4 20:58

Up to $2.967 Billion! Innovative Biopharma Signs Landmark Overseas Deal | Selected After-Hours Announcements

A innovative pharmaceutical company has signed a major overseas deal; a leading stock in the intelligent computing sector plans to raise nearly RMB 2.9 billion through a private placement to invest in intelligent computing center construction; and the chairman of an agricultural and livestock giant has been replaced.

Golden10 DataJun 1 20:52

Breaking News! Two High-Performing Stocks Clarify Relationship with NVIDIA and Issue Risk Warnings | After-Hours Announcement Roundup

Amoy Diagnostics: Planning Change in Control; Trading Halted

cls.cnMay 31 19:33

Pharmaron to Invest RMB 5 Billion to Expand Capacity in Hangzhou and Shaoxing Following Collaboration with Eli Lilly and Co | Announcement Highlights

① Pharmaron plans to invest RMB 5 billion to build a facility in Shaoxing with an annual capacity of 200 tons of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), and to establish a CDMO R&D and manufacturing services hub in Hangzhou; ② The Shaoxing project focuses on scaling up production capacity, while the Hangzhou project emphasizes CDMO R&D and manufacturing services, creating a complementary and differentiated setup; ③ The company previously entered into a manufacturing partnership with Eli Lilly and Co. for Orforglipron, a GLP-1 drug.

cls.cnMay 27 22:31

Former market darling sees entire stake held by controlling shareholder frozen! | Selected Post-Market Announcements

The former semiconductor giant’s controlling shareholder, holding 100% of its shares, has had its stake judicially frozen; the leading provider of memory interface chips has preliminarily set a transfer price of RMB 250.08 per share; and the PCB-related stock, which has seen two consecutive daily trading limits, announced that its controlling shareholder and parties acting in concert have completed their share reduction...

Golden10 DataMay 25 21:02

Morning Brief by Xiao K | National Data Bureau: Will incorporate promoting token economy development into its work framework; DeepSeek announces permanent price reduction

① The Shenzhou-23 crewed spacecraft was successfully launched; ② Henan’s 15th Five-Year Plan Outline: Promote green and low-carbon development of computing power; ③ Google and AMD have been removed from the Russell 1000 Value Index.

cls.cnMay 25 07:53

Baicheng Pharma Plans Control Rights Change; CRO Sector Consolidation Accelerates | Quick Read Announcement

① The actual controller of Baicheng Pharma is planning a change in control, and trading of its shares will be suspended starting May 25; ② Since its listing, Baicheng Pharma's financial performance initially rose before declining, with its full-year net loss widening to RMB 900 million in 2025, though it returned to profitability in Q1 2026; ③ In 2026, consolidation in the CRO industry is accelerating.

cls.cnMay 24 21:11

A premier oncology pharmaceutical summit will be held next week, with multiple innovative drug-focused listed companies issuing related announcements. Institutions noted the conference could catalyze market sentiment in the sector.

① In 2025, innovative drug companies generated total revenue of RMB 65.698 billion, an increase of 38.23% year-over-year. In Q1 2026, they reported total revenue of RMB 17.642 billion, up 40.32% year-over-year; ② In Q1 2026, outbound licensing deals exceeded USD 60 billion, with transactions in cutting-edge areas such as ADCs and bispecific antibodies remaining highly active.

cls.cnMay 23 16:28

At what point should one sell AI technology stocks?

The AI technology sector trend has not yet run its course, but the question of 'where is the selling point?' has already begun troubling a significant number of investors. As the ChiNext Index—represented by the 'Xinning Portfolio' (referring to the two core themes of 'AI-driven price increases' and 'overseas expansion of new energy,' both of which have consistently demonstrated high industry momentum)—continues to rise, investors face an unavoidable practical decision: Should they sell incrementally as prices climb, or wait for a clear signal before exiting? On May 21, Lin Rongxiong, a strategy analyst at Guotou Securities, offered a relatively clear assessment in his latest research report: Based on the N-shaped pricing pattern typical of tech investments, the so-called 'selling point' (Point D) is better understood as

wallstreetcnMay 22 11:27

Policy breakthrough: out-of-pocket influenza vaccines may now be covered by medical insurance, potentially boosting vaccination willingness and creating a stimulative effect.

① The policy may directly boost vaccination willingness, particularly exerting a positive pull effect among working populations and elderly individuals and children covered under family mutual aid schemes; ② Given the current industry supply-demand dynamics, the prevailing low-price competition in the influenza vaccine market is unlikely to reverse in the short term. However, as vaccine manufacturers continue public education campaigns that raise public awareness and vaccination intent—combined with steadily expanding payment channels for vaccines—the industry’s operating conditions are expected to gradually stabilize.

cls.cnMay 19 21:20

Optical Fiber Bull Stock Clarification: The Company Has No Business Relationship with NVIDIA! | After-Hours Announcement Highlights

Optical fiber stock urgently clarifies no connection with NVIDIA! Stock with five limit-up days in seven trading sessions issues risk warning; pharmaceutical giant announces its holding subsidiary has signed an exclusive option agreement.

Golden10 DataMay 13 21:02

No business relationship with NVIDIA whatsoever! A 33 billion yuan fiber-optic concept stock releases clarification announcement | Post-market announcements summary

China Jushi: Plans to invest 4.431 billion yuan in building a production line project for 50,000 tons of electronic yarn and 320 million meters of electronic cloth annually

cls.cnMay 13 20:42

Low stock prices prompt shareholders to urge share repurchases; Kanghong Pharmaceutical plans to invest over 1 billion yuan annually in R&D in the future | Earnings meeting coverage

①During the earnings call, several participants expressed dissatisfaction with the current stock price of Kanghong Pharmaceutical and suggested that the company take various measures to boost investor confidence; ②Kanghong Pharmaceutical also shared updates on the progress of its highly anticipated R&D pipeline.

cls.cnMay 11 20:04

Zhifei Biological Products stated that it would adopt multiple measures to reduce market risks amid criticism over its stock price having 'fallen to nothing.' | Earnings Call Highlights

① Investors at the ZhiFei Bio earnings meeting generally focused on the measures the company plans to adopt to stabilize its financial condition; ② The company stated that due to fluctuating market demand and other factors, its short-term performance remains under pressure.

cls.cnMay 8 22:18

This company signs a major computing power service contract with a maximum value of 19 billion yuan | Post-market announcement highlights

Jinli Huadian: Plans to purchase equity in Zhongke Xiguang; trading suspension begins on May 6.

cls.cnMay 5 19:12

The dual drivers of the silver economy and the younger generation's focus on health have made the tonic category the main growth engine of the traditional Chinese medicine industry.

① According to the annual report data disclosed by listed companies in 2025, tonic medicines have become the most certain growth track in the traditional Chinese medicine industry; ② Judging from the new product layouts of various proprietary Chinese medicine enterprises, the level of emphasis placed on the tonic track by these companies has also significantly increased.

cls.cnMay 1 22:02